FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 317:461-467 August 20, 1987 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Chemoradiotherapy and transplantation of bone marrow from matched sibling donors have been useful for the treatment of acute lymphoblastic leukemia in patients with a poor prognosis but are not available to some two thirds of patients who do not have a matched allogeneic donor. We undertook this study to compare autologous and allogeneic marrow transplantation in the treatment of such cases. We treated 91 patients with high-dose chemoradiotherapy and followed them for 1.4 to 5 years. Forty-six patients with an HLA-matched donor received allogeneic marrow, and 45 patients without a matched donor received their own marrow taken during remission and purged of leukemic cells with use of monoclonal antibodies. Bone marrow engraftment occurred earlier in patients who received autologous marrow. Recipients of autologous marrow had shorter hospital courses, with significantly fewer peritransplantation deaths than recipients of allogeneic marrow. Post-transplantation relapse of leukemia was the most frequent cause of treatment failure; relapses occurred in an estimated 37 percent of patients with allogeneic grafts in whom graft-versus-host disease developed, 75 percent of patients with allogeneic grafts in whom graft-versus-host disease did not develop, and 79 percent of patients who received autologous grafts. The interval before relapse was significantly shorter in the autologous-marrow group than in the allogeneic-marrow group. Recipients of autologous and allogeneic marrow whose first pretransplantation remissions were short (less than 18 months) had eventual outcomes similar to those whose first remissions were longer than 18 months. Patients with a first remission lasting less than 18 months had an outcome better than that expected with chemotherapy alone. The fractions of "cured" patients were estimated to be 20 percent in the autologous-marrow group and 27 percent in the allogeneic-marrow group--not a significant difference, but because of the limited statistical power of the study, the question of long-term disease-free survival must still be considered open.

This article has been cited by other articles:

• Mohty, M., Bay, J.-O., Faucher, C., Choufi, B., Bilger, K., Tournilhac, O., Vey, N., Stoppa, A.-M., Coso, D., Chabannon, C., Viens, P., Maraninchi, D., Blaise, D. (2003). Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102: 470-476 [Abstract] [Full Text]  
• McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., Radich, J., Wagner, J. L., Minor, S., Appelbaum, F. R., Bensinger, W. I., Bryant, E., Flowers, M. E. D., Georges, G. E., Grumet, F. C., Kiem, H.-P., Torok-Storb, B., Yu, C., Blume, K. G., Storb, R. F. (2001). Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400 [Abstract] [Full Text]  
• Baynes, R. D., Hamm, C., Dansey, R., Klein, J., Cassells, L., Karanes, C., Abella, E., Peters, W. P. (2000). Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting. Clin. Chem. 46: 1239-1251 [Abstract] [Full Text]  
• Borrello, I., Sotomayor, E. M., Rattis, F.-M., Cooke, S. K., Gu, L., Levitsky, H. I. (2000). Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95: 3011-3019 [Abstract] [Full Text]  
• Felix, C. A., Lange, B. J., Chessells, J. M. (2000). Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. ASH Education Book 2000: 285-302 [Abstract] [Full Text]  
• Vallera, D. A., Seo, S.-Y., Panoskaltsis-Mortari, A., Griffin, J. D., Blazar, B. R. (1999). Targeting myeloid leukemia with a DT390-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng Des Sel 12: 779-785 [Abstract] [Full Text]  
• Uckun, F. M., Tuel-Ahlgren, L., Waddick, K. G., Jun, X., Jin, J., Myers, D. E., Rowley, R. B., Burkhardt, A. L., Bolen, J. B. (1996). Physical and Functional Interactions between Lyn and p34[IMAGE] Kinases in Irradiated Human B-cell Precursors. J. Biol. Chem. 271: 6389-6397 [Abstract] [Full Text]  
• Armitage, J. O. (1994). Bone Marrow Transplantation. NEJM 330: 827-838 [Full Text]  
• Uckun, F. M., Kersey, J. H., Haake, R., Weisdorf, D., Nesbit, M. E., Ramsay, N. (1993). Pretransplantation Burden of Leukemic Progenitor Cells as a Predictor of Relapse after Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. NEJM 329: 1296-1301 [Abstract] [Full Text]